DBV Technologies Stock Declines 2% and Tests Support at €2.31
The Châtillon biotech company has turned negative again this Friday, following a rebound recorded on Wednesday, September 2. The stock is testing its support level during trading in a generally stable Paris market, with the SBF 120 itself declining by less than half a point.
Support at €2.31 Briefly Touched During Session, Below Three Deteriorating Moving Averages
DBV Technologies is down 2.2% to €2.31 during trading, exactly at its support level threshold. The stock briefly broke through this floor downwards during the session before recovering above it, illustrating the fragility of the current configuration. Pressure is accumulating from above: the price is below the MA20 at €2.44 (5.16% gap), below the MA50 at €2.56 (9.61% gap) and below the MA200 at €3.14 (26.31% gap).
These three moving averages form a tiered resistance that has been capping the stock for several weeks, to the point that the quarterly decline has reached nearly 24%. The RSI at 44 remains in neutral territory, with no clear signal of seller exhaustion. If the €2.31 support clearly gives way, the next visible reference is the inverted resistance at €2.57, currently out of reach in the immediate term.
Rising Short Positions Over One Month and Q1 Loss Widening Weigh on Valuation
According to recorded declarations, three funds collectively hold 3.51% of DBV Technologies capital in net short position, a level up 0.39 points over thirty days (it was at 3.12% one month ago). At this threshold, the bearish bet remains significant and reflects persistent institutional distrust, without signaling a sharp acceleration. These positions should be read in parallel with the fundamental data published during the Q1 2026 results (published April 30, 2026), which showed a net loss increasing to 47.6 million dollars and a significant increase in R&D spending.
Against this backdrop, the analyst consensus on the stock remains an element to monitor, especially since the company was targeting, during this same publication, the filing of its biological license application in 2026. Over one year, the stock remains up nearly 50%, which testifies to a contrasted performance against a short-term momentum that is now negative.
